Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint
To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ). 70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st ( =3...
Gespeichert in:
Veröffentlicht in: | Terapevtic̆eskii arhiv 2023-12, Vol.95 (12), p.1141 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | rus |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 12 |
container_start_page | 1141 |
container_title | Terapevtic̆eskii arhiv |
container_volume | 95 |
creator | Mazurov, V I Belyaeva, I B Trofimov, E A Itskovich, I E Burulev, A L |
description | To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ).
70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st (
=35) took AN 1 caps/day, in the 2nd (
=35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators.
Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups.
The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice. |
format | Article |
fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_38785054</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38785054</sourcerecordid><originalsourceid>FETCH-pubmed_primary_387850543</originalsourceid><addsrcrecordid>eNqFkE1OAzEMRgeJilbQKyAfoJVSTf_WFBDds6_cxNNJSZxR4ima25NUZcWClfXZT8-y76uJUks1r9drNa6mKZ2VUovlar3YbB6qcb3dbFdqtZzcjXbBdxhR7IWAmsZq1AOEBhB08EfLeRK4NHo2lFMfyYAMHcF-nxHn8EQ8g5eQvsk5qwG1NWkGnqQdXOpdE3hwJSHTDC5W0FtOsANkA69QX-ufbboNbGKwYhmKBIWu4Mn1OqSiIGiHTOjWhWgNQQalJZBIKJ5YiqWL1mPM9yShgFHamIWpTAr6xURwDpblqRo16BJNb_Wxen5_-9x9zLv-6Mkcbp7D79_qf4EfD45_1g</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><creator>Mazurov, V I ; Belyaeva, I B ; Trofimov, E A ; Itskovich, I E ; Burulev, A L</creator><creatorcontrib>Mazurov, V I ; Belyaeva, I B ; Trofimov, E A ; Itskovich, I E ; Burulev, A L</creatorcontrib><description>To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ).
70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st (
=35) took AN 1 caps/day, in the 2nd (
=35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators.
Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups.
The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.</description><identifier>ISSN: 0040-3660</identifier><identifier>PMID: 38785054</identifier><language>rus</language><publisher>Russia (Federation)</publisher><subject><![CDATA[Aged ; Ascorbic Acid - administration & dosage ; Ascorbic Acid - pharmacology ; Chondroitin Sulfates - administration & dosage ; Chondroitin Sulfates - pharmacology ; Collagen Type II - administration & dosage ; Dimethyl Sulfoxide - administration & dosage ; Dimethyl Sulfoxide - pharmacology ; Drug Therapy, Combination ; Female ; Glucosamine - administration & dosage ; Glucosamine - pharmacology ; Humans ; Male ; Middle Aged ; Osteoarthritis, Knee - drug therapy ; Pain Measurement ; Quality of Life ; Severity of Illness Index ; Sulfones - administration & dosage ; Sulfones - pharmacology ; Treatment Outcome ; Triterpenes - administration & dosage ; Triterpenes - pharmacology]]></subject><ispartof>Terapevtic̆eskii arhiv, 2023-12, Vol.95 (12), p.1141</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-8352-3955 ; 0009-0007-5401-5047 ; 0000-0002-0797-2051 ; 0000-0003-3236-4485 ; 0000-0002-7981-6349</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38785054$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazurov, V I</creatorcontrib><creatorcontrib>Belyaeva, I B</creatorcontrib><creatorcontrib>Trofimov, E A</creatorcontrib><creatorcontrib>Itskovich, I E</creatorcontrib><creatorcontrib>Burulev, A L</creatorcontrib><title>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</title><title>Terapevtic̆eskii arhiv</title><addtitle>Ter Arkh</addtitle><description>To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ).
70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st (
=35) took AN 1 caps/day, in the 2nd (
=35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators.
Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups.
The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.</description><subject>Aged</subject><subject>Ascorbic Acid - administration & dosage</subject><subject>Ascorbic Acid - pharmacology</subject><subject>Chondroitin Sulfates - administration & dosage</subject><subject>Chondroitin Sulfates - pharmacology</subject><subject>Collagen Type II - administration & dosage</subject><subject>Dimethyl Sulfoxide - administration & dosage</subject><subject>Dimethyl Sulfoxide - pharmacology</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Glucosamine - administration & dosage</subject><subject>Glucosamine - pharmacology</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Osteoarthritis, Knee - drug therapy</subject><subject>Pain Measurement</subject><subject>Quality of Life</subject><subject>Severity of Illness Index</subject><subject>Sulfones - administration & dosage</subject><subject>Sulfones - pharmacology</subject><subject>Treatment Outcome</subject><subject>Triterpenes - administration & dosage</subject><subject>Triterpenes - pharmacology</subject><issn>0040-3660</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1OAzEMRgeJilbQKyAfoJVSTf_WFBDds6_cxNNJSZxR4ima25NUZcWClfXZT8-y76uJUks1r9drNa6mKZ2VUovlar3YbB6qcb3dbFdqtZzcjXbBdxhR7IWAmsZq1AOEBhB08EfLeRK4NHo2lFMfyYAMHcF-nxHn8EQ8g5eQvsk5qwG1NWkGnqQdXOpdE3hwJSHTDC5W0FtOsANkA69QX-ufbboNbGKwYhmKBIWu4Mn1OqSiIGiHTOjWhWgNQQalJZBIKJ5YiqWL1mPM9yShgFHamIWpTAr6xURwDpblqRo16BJNb_Wxen5_-9x9zLv-6Mkcbp7D79_qf4EfD45_1g</recordid><startdate>20231228</startdate><enddate>20231228</enddate><creator>Mazurov, V I</creator><creator>Belyaeva, I B</creator><creator>Trofimov, E A</creator><creator>Itskovich, I E</creator><creator>Burulev, A L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><orcidid>https://orcid.org/0000-0001-8352-3955</orcidid><orcidid>https://orcid.org/0009-0007-5401-5047</orcidid><orcidid>https://orcid.org/0000-0002-0797-2051</orcidid><orcidid>https://orcid.org/0000-0003-3236-4485</orcidid><orcidid>https://orcid.org/0000-0002-7981-6349</orcidid></search><sort><creationdate>20231228</creationdate><title>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</title><author>Mazurov, V I ; Belyaeva, I B ; Trofimov, E A ; Itskovich, I E ; Burulev, A L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_387850543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>rus</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Ascorbic Acid - administration & dosage</topic><topic>Ascorbic Acid - pharmacology</topic><topic>Chondroitin Sulfates - administration & dosage</topic><topic>Chondroitin Sulfates - pharmacology</topic><topic>Collagen Type II - administration & dosage</topic><topic>Dimethyl Sulfoxide - administration & dosage</topic><topic>Dimethyl Sulfoxide - pharmacology</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Glucosamine - administration & dosage</topic><topic>Glucosamine - pharmacology</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Osteoarthritis, Knee - drug therapy</topic><topic>Pain Measurement</topic><topic>Quality of Life</topic><topic>Severity of Illness Index</topic><topic>Sulfones - administration & dosage</topic><topic>Sulfones - pharmacology</topic><topic>Treatment Outcome</topic><topic>Triterpenes - administration & dosage</topic><topic>Triterpenes - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazurov, V I</creatorcontrib><creatorcontrib>Belyaeva, I B</creatorcontrib><creatorcontrib>Trofimov, E A</creatorcontrib><creatorcontrib>Itskovich, I E</creatorcontrib><creatorcontrib>Burulev, A L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Terapevtic̆eskii arhiv</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazurov, V I</au><au>Belyaeva, I B</au><au>Trofimov, E A</au><au>Itskovich, I E</au><au>Burulev, A L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint</atitle><jtitle>Terapevtic̆eskii arhiv</jtitle><addtitle>Ter Arkh</addtitle><date>2023-12-28</date><risdate>2023</risdate><volume>95</volume><issue>12</issue><spage>1141</spage><pages>1141-</pages><issn>0040-3660</issn><abstract>To evaluate the efficacy of Artneo (AN) in comparison with a combination of glucosamine hydrochloride and chondroitin sulfate (GC) in patients with osteoarthritis (OA) of the knee joint (KJ).
70 patients with stages I-III of primary knee OA were randomized into 2 groups. Participants in the 1st (
=35) took AN 1 caps/day, in the 2nd (
=35) GC according to the standard regimen. After 7, 30, 90, 180 days, the Lequesne index (severity of OA), pain when moving according to VAS, WOMAC score were assessed, after 1, 3, 6 months - quality of life SF-36 and morning stiffness, after 6 months - MRI with T2 mapping, laboratory safety indicators.
Over the course of 6 months of use, an improvement in the WOMAC index and a decrease in pain were observed without intergroup differences, and a greater decrease in stiffness in the AN group. After 3 months, the severity of OA decreased from moderate to mild in the AN group and was significantly lower compared to the GC group; quality of life (physical component of SF-36) was higher in the AN group. After 6 months, there was an improvement in cartilage ultrastructure (T2 relaxation time) in both groups and a more pronounced reduction of the synovitis area (MRI) in the AN group (2.95 and 1.37 times in the AN and GC group, respectively). There were no clinically significant adverse reactions observed in both groups.
The use of AN in patients with stage I-III primary knee OA was not inferior in efficacy to the combination of GC. Further studies with greater statistical power (sample size) and follow-up period are warranted including in real clinical practice.</abstract><cop>Russia (Federation)</cop><pmid>38785054</pmid><orcidid>https://orcid.org/0000-0001-8352-3955</orcidid><orcidid>https://orcid.org/0009-0007-5401-5047</orcidid><orcidid>https://orcid.org/0000-0002-0797-2051</orcidid><orcidid>https://orcid.org/0000-0003-3236-4485</orcidid><orcidid>https://orcid.org/0000-0002-7981-6349</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0040-3660 |
ispartof | Terapevtic̆eskii arhiv, 2023-12, Vol.95 (12), p.1141 |
issn | 0040-3660 |
language | rus |
recordid | cdi_pubmed_primary_38785054 |
source | MEDLINE; DOAJ Directory of Open Access Journals |
subjects | Aged Ascorbic Acid - administration & dosage Ascorbic Acid - pharmacology Chondroitin Sulfates - administration & dosage Chondroitin Sulfates - pharmacology Collagen Type II - administration & dosage Dimethyl Sulfoxide - administration & dosage Dimethyl Sulfoxide - pharmacology Drug Therapy, Combination Female Glucosamine - administration & dosage Glucosamine - pharmacology Humans Male Middle Aged Osteoarthritis, Knee - drug therapy Pain Measurement Quality of Life Severity of Illness Index Sulfones - administration & dosage Sulfones - pharmacology Treatment Outcome Triterpenes - administration & dosage Triterpenes - pharmacology |
title | Comparative efficacy of a combination of undenatured type II collagen, Boswellic acids, methylsulfonylmethane, vitamins C and D 3 and a combination of chondroitin sulfate and glucosamine hydrochloride in the treatment of primary osteoarthritis of the knee joint |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T02%3A32%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20efficacy%20of%20a%20combination%20of%20undenatured%20type%20II%20collagen,%20Boswellic%20acids,%20methylsulfonylmethane,%20vitamins%20C%20and%20D%203%20and%20a%20combination%20of%20chondroitin%20sulfate%20and%20glucosamine%20hydrochloride%20in%20the%20treatment%20of%20primary%20osteoarthritis%20of%20the%20knee%20joint&rft.jtitle=Terapevtic%CC%86eskii%20arhiv&rft.au=Mazurov,%20V%20I&rft.date=2023-12-28&rft.volume=95&rft.issue=12&rft.spage=1141&rft.pages=1141-&rft.issn=0040-3660&rft_id=info:doi/&rft_dat=%3Cpubmed%3E38785054%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38785054&rfr_iscdi=true |